Renal amyloidosis;Amyloïdose rénale

Revue Medicale Suisse

Volumn 8, Issue 330, 2012, Pages 446-451

  Cuchard, P ^a   Cuchard, R ^a   Rotman, S ^b   Burnier, M ^c   Gauthier, T ^a  

^a Hopital Riviera   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOIDOSIS; BETA SHEET; BIOPSY; CHRONIC INFLAMMATION; GASTROINTESTINAL TRACT; HEART; HEART AMYLOIDOSIS; HUMAN; KIDNEY; KIDNEY AMYLOIDOSIS; LIGHT CHAIN; PROGNOSIS; PROTEIN STRUCTURE; RENAL REPLACEMENT THERAPY; REVIEW; AGED; CASE REPORT; CHRONIC KIDNEY FAILURE; DISEASE COURSE; INCIDENCE; KIDNEY DISEASE; MALE;

AGED; AMYLOIDOSIS; DISEASE PROGRESSION; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84860330184     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Wilks S. Cases of lardaceous disease and some allied affections. With remarks. Guy's Hospital Reports 1856;2:103.
2. Weber H. Mollities ossium, doubtful whether carcinomatous or syphilitic. Transactions of the Pathological Society of London 1867;18:206.
3. * Kyle RA. Amyloidosis: A convoluted story. Br J Haematol 2001;114:529-38.
4. Solomon A, Weiss DT, Pepys MB. Induction in mice of human light-chain-associated amyloidosis. Am J Pathology 1992;140:629-37.
5. Bellotti V, Nuvolone M, Giorgetti S, et al. The workings of the amyloid diseases. Ann Med 2007;39:200-7.
6. Madan S, Dispenzieri A, Lacy MQ, et al. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diag nosis of multiple myeloma. Mayo Clin Proc 2010;85:232-8.
7. Rajkumar SV, Gertz MA, Kyle RA. Primary systemic amyloidosis with delayed progression to multiple myeloma. Cancer 1998;82:1501-5.
8. Kyle RA, Therneau TM, Rajkumar SV, et al. A longterm study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-9.
9. Neugarten J, Gallo GR, Buxbaum J, et al. Amyloidosis in subcutaneous heroin abusers («skin poppers'amyloidosis»). Am J Med 1986;81:635-40.
10. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490-7.
11. Gertz MA, Leung N, Lacy MQ, et al. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant 2009;24:3132-7.
12. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica 2009;94:1044-8.
13. Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc 1983;58:665-83.
14. Falck HM, Törnroth T, Wegelius O. Predominantly vascular amyloid deposition in the kidney in patients with minimal or no proteinuria. Clin Nephrol 1983;19:137-42.
15. ** Falk RH, Skinner M. The systemic amyloidoses: An overview. Adv Intern Med 2000;45:107-37.
16. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005;95:535-7.
17. Chamarthi B, Dubrey SW, Cha K, et al. Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 1997;80:1242-5.
18. Ebert EC, Nagar M. Gastrointestinal manifestations of amyloidosis. Am J Gastroenterol 2008;103:776-87.
19. Guirl MJ, Högenauer C, Santa Ana CA, et al. Rapid intestinal transit as a primary cause of severe chronic diarrhea in patients with amyloidosis. Am J Gastroenterol 2003;98:2219-25.
20. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-23.
21. Sucker C, Hetzel GR, Grabensee B, et al. Amyloidosis and bleeding: Pathophysiology, diagnosis, and therapy. Am J Kidney Dis 2006;47:947-55.
22. Dhingra S, Krishnani N, Kumari N, Pandey R. Evaluation of abdominal fat pad aspiration cytology and grading for detection in systemic amyloidosis. Acta Cytol 2007;51:860-4.
23. Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002;346:1786-91.
24. Leung N, Dispenzieri A, Lacy MQ, et al. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation. Clin J Am Soc Nephrol 2007;2:440-4.
25. Fushimi T, Takahashi Y, Kashima Y, et al. Severe protein losing enteropathy with intractable diarrhea due to systemic AA amyloidosis, successfully treated with corticosteroid and octreotide. Amyloid 2005;12:48-53.
26. Sherif AM, Refaie AF, Sobh MA, et al. Long-term outcome of live donor kidney transplantation for renal amyloidosis. Am J Kidney Dis 2003;42:370-5.
27. Pepys MB, Herbert J, Hutchinson WL, et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002;417:254-9.
28. Pardanani A, Witzig TE, Schroeder G, et al. Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis. Blood 2003;101:827-30.
29. Palladini G, Campana C, Klersy C, et al. Serum Nterminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-5.